Edwards Lifesciences Insiders Sell Stakes Amid Late August Stock Activity, No New FDA or Earnings News

Edwards Lifesciences (NYSE: EW) saw multiple insider stock sales over the past week, according to recent filings, although there were no new regulatory approvals, earnings reports or other material developments directly impacting the company’s outlook during that time.

Notable Insider Stock Sales

Data from Investing.com shows that Andrew M. Dahl, Edwards’ Senior Vice President and Corporate Controller, sold shares valued at approximately $49,533 roughly nine hours ago. Similarly, Daveen Chopra, Corporate Vice President of Transcatheter Mitral and Tricuspid Therapies, Surgical & IHFM, offloaded about $2.9 million in stock on August 26, 2026. Wayne Markowitz, Corporate Vice President for Japan & Asia Pacific, executed multiple sales totaling $113,416 on August 26 and another transaction of $12,587 on July 30. Daniel J. Lippis, the CVP for TAVR, also sold approximately $56,966 in stock on August 11, 2026. These disclosures indicate significant insider liquidity actions spanning from mid-July through late August. 

Absent New Catalyst in Medtech

In contrast, there were no new disclosures in the past week regarding FDA approvals, fresh product indications, earnings upgrades, or other events directly tied to Edwards’ core structural heart business. The company’s most recent material update remains its second-quarter 2026 earnings report issued on July 23, which included raised sales and TAVR guidance and signaled continued momentum across its product portfolio. 

What Investors Should Know

The insider sales may attract investor attention as potential signals of reduced confidence or personal liquidity needs, though they offer no direct insight into company fundamentals without accompanying commentary. With no fresh news in the past seven days, EW remains in a holding pattern rigidly defined by its Q2 results and ongoing CMS review due this September.

Stock Price Note: As of September 2, 2026, EW shares were trading at $90.82, down 0.71% on that day. 

Investors may wish to keep an eye on the upcoming CMS National Coverage Determination decision for TAVR and any forthcoming investor presentations slated for mid-September, which could introduce new catalysts.